Please login to the form below

Not currently logged in
Email:
Password:

Increlex

This page shows the latest Increlex news and features for those working in and with pharma, biotech and healthcare.

EMA publishes European drug shortage details

EMA publishes European drug shortage details

First public list contains details on Cerezyme, Fabrazyme, Increlex and Vistide. ... The two other drugs with shortages assessed by the EMA are Ipsen's Increlex (mecasermin), for people with a growth disorder due to severe primary insulin-like growth

Latest news

  • North-South divide?

    As such, treatments for high need, orphan conditions have been approved with costs per QALY potentially above £40, 000 (46, 000), like mecasermin (Increlex) for growth failure in children and nelarabine

  • Reaching new heights

    A compelling video illustrated the case of the first UK patient diagnosed with Severe Primary IGFD and treated with Recombinant human insulin-like growth factor-I (rhIGF-I), Increlex. ... 75 per cent were 'considerably more confident' in using rhIGF-1

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics